|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial显示文摘AIM: To estimate if and to what extent long acting octreotide (LAR) improves survival and quality of life in patients with advanced hepatocellular carcinoma (HCC). METHODS: A total of 127 cirrhotics, stages A-B, due to chronic viral infections and with advanced HCC, were enrolled in the study. Scintigraphy with 111Indium labeled octreotide was performed in all cases. The patients with increased accumulation of radionuclear compound were randomized to receive either oral placebo only or octreotide/octreotide LAR only as follows: octreotide 0.5mg s.c. every 8 h for 6 wk, at the end of wk 4-8 octreotide LAR 20 mg i.m. and at the end of wk 12 and every 4 wk octreotide LAR 30mg i.m.. Follow-up was worked out monthly as well as the estimation of quality of life (QLQ-C30 questionnaire). Patients with negative somatostatin receptors (SSTR) detection were followed up in the same manner. RESULTS: Scintigraphy demonstrated SSTR in 61 patients. Thirty were randomized to receive only placebo and 31 only octreotide. A significantly higher survival time was observed for the octreotide group (49 ± 6 wk) as compared to the control group (28 ± 1 wk) and to the SSTR negative group (28 ± 2 wk), LR = 20.39, df = 2, P < 0.01. The octreotide group presented 68.5% lower hazard ratio [95% CI (47.4%-81.2%)]. During the f irst year, a 22%, 39% and 43% decrease in the QLQ-C30 score was observed in each group respectively.CONCLUSION: The proposed therapeutic approach has shown to improve the survival and quality of life in SSTR positive patients with advanced HCC. | D Dimitroulopoulos D Xinopoulos K Tsamakidis A Zisimopoulos E Andriotis D Panagiotakos A Fotopoulou C Chrysohoou A Bazinis D Daskalopoulou E Paraskevas | 2007 | World Journal of Gastroenterology2007，13，23： | 18 |
| 2 | Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP显示文摘AIM: To investigate the technical success and clinical complication rate of a cannulated pancreatic duct with guidewire for biliary access. METHODS: During a five-year study period, a total of 2843 patients were included in this retrospective analysis. Initial biliary cannulation method consisted of single-guidewire technique (SGT) for up to 5 attempts, followed by double-guidewire technique (DGT) when repeated unintentional pancreatic duct cannulation had taken place. Pre-cut papillotomy technique was reserved for when DGT had failed or no pancreatic duct cannulation had been previously achieved. Main outcome measurements were defined as biliary cannu-lation success and post-endoscopic retrograde cholangiopancreatography (ERCP) complication rate. RESULTS: SGT (92.3% success rate) was characterized by statistically significant enhanced patient outcome compared to either the DGT (43.8%, P < 0.001), pre-cut failed DGT (73%, P < 0.001) or pre-cut as first step method (80.6%, P = 0.002). Pre-cut as first step method offered a statistically significantly more favorable outcome compared to the DGT (P < 0.001). The incidence of post-ERCP pancreatitis did not differ in a statistically significant manner between either method (SGT: 5.3%, DGT: 6.1%, Pre-cut failed DGT: 7.9%, Pre-cut as first step: 7.5%) or with patients' gender. CONCLUSION: Although DGT success rate proved not to be superior to SGT or pre-cut papillotomy, it is considered highly satisfactory in terms of safety in order to avoid the risk of a pre-cut when biliary therapy is necessary in difficult-to-cannulate cases. | Dimitrios Xinopoulos Stefanos P Bassioukas Dimitrios Kypreos Dimitrios Korkolis Andreas Scorilas Konstantinos Mavridis Dimitrios Dimitroulopoulos Emmanouil Paraskevas | 2011 | World Journal of Gastroenterology2011，17，15： | 8 |
| 3 | Solitary fibrous tumor of the liver expressing CD34 and vimentin:A case report显示文摘A case of a successfully treated solitary fibrous tumor (SFT) of the liver is reported.An 82-year-old female presented with left upper abdominal discomfort,a firm mass on palpation,and imaging studies revealed a large tumor,15 cm in diameter,arising from the left lobe of the liver.A formal left hepatectomy was performed.Microscopic evaluation showed spindle and fibroblast-like cells within the collagenous stroma.Immunohistochemistry disclosed diffuse CD34 and positive vimentin,supporting the diagnosis of a benign SFT.The patient remained well 21 months after surgery.SFT of the liver is a very rare neoplasm of mesenchymal origin.In most cases it is a benign lesion,although some may have malignant histological features and recur locally or metastasize.With less than 30 reported cases in the literature,little can be said regarding its natural history or the benefits of adjuvant radiochemotherapy.Complete surgical resection remains the cornerstone of its treatment. | Dimitris P Korkolis Katerina Apostolaki Chrysanthi Aggeli George Plataniotis Emmanuel Gontikakis Dimitra Volanaki Maria Sebastiadou Dimitris Dimitroulopoulos Dimitris Xinopoulos George N Zografos Perikles P Vassilopoulos | 2008 | World Journal of Gastroenterology2008，14，40： | 3 |
| 4 | The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘 | Dimitroulopoulos D Xinopoulos D Tsamakidis K | 2002 | Hepato-gastroenterology2002，49，47： | 1 |
| 5 | Treatment of malignant colonic obstructions with metal stents and laser显示文摘 | Xinopoulos D Dimitroulopoulos D Tsamakidis K | 2002 | Hepatogastroenterology2002，49，44： | 1 |
| 6 | Large-scale expansion of CD3 + CD56 + lymphocytes ca- pable of lysing autologous tumor ceils with cytokine-rich supernatants 显示文摘 | Gritzapis A D Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 7 | Large scale expansion of CD3(+)CD56(+)lymphocytes capable of lysing autologoustumor cells with cytokine rich supernatants显示文摘 | Gritzapis AD Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，： | 1 |
| 8 | Palliative treatment of advanced esophageal cancer with metal-covered expandable stents:a cost-effectiveness and quality of life study显示文摘 | Xinopoulos D Dimitroulopoulos D Tsamakidis K | 2005 | J BUON2005，10，4： | 1 |
| 9 | Large scale expansion of CD3^+ CD56^+ lymphocytes capa- ble of lysing autologous tumor cells with cytokine-rich supernatants 显示文摘 | Gritzapis AD Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 10 | The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘 | Dimitroulopoulos D Xinopoulos D Tsamakidis K | 2002 | Hepatogastroenterology2002，49，47： | 1 |
| 11 | Large- scale expansion of CD3(+)CD56(+) lymphoeytes capable of lysing autologous tumor cells with cytokine-rich supernatants 显示文摘 | Gritzapis AD Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 12 | Largescale expansion of CD3(+)CD56(+)lymphocytes capable of lysing autologuous tumor cells with cytokine-rich supematants显示文摘 | Gritzapis AD Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 13 | large scale expansion of CD3^+ CD56^+ lymphocytes capable of lysing autologous tumor cells with cytokine r/oh supematants CD3^+ CD56^+ 显示文摘 | Gritznpis AD Dimitroulopoulos D Paraskcvas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 14 | The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘 | Dimitroulopoulos D Xinopoulos D Tsamakidis K | 2002 | Hepatogastroenterology2002，49，47： | 1 |
| 15 | Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants显示文摘 | A. Gritzapis D. Dimitroulopoulos E. Paraskevas C. Baxevanis M. Papamichail | 2002 | Cancer Immunology Immunotherapy2002，，8： | 1 |
| 16 | The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘 | Dimitroulopoulos D Xinopoulos D Tsamakidis K | 2002 | Hepatogastroenterology2002，49，47： | 1 |
| 17 | The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘 | Dimitroulopoulos D Xinopoulos D Tsamakidis K | 2002 | Hepatogastroenterology2002，49，： | 1 |
| 18 | Large-scale expansion of CD3 (+)CD56 (+)lymphocytes capable of lysing autologous tumor cells with cytokine- rich supernatants 显示文摘 | Gritzapis AD Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
| 19 | Palliative treatment of advanced esophageal cancer with metal-covered expandable stents:A cost-effectiveness and quality of life study显示文摘 | Xinopoulos D Dimitroulopoulos D Tsamakidis K | | 0，，04： | 1 |
| 20 | Large-scale expansion of CD3 ( + ) CD56 ( + ) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants显示文摘 | Gritzapis A D Dimitroulopoulos D Paraskevas E | 2002 | Cancer Immunol Immunother2002，51，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员